目的 研究艾地苯醌聯(lián)合多巴絲肼治療帕金森病的臨床療效及其對α-突觸核蛋白（α-Syn）、生長分化因子-15（GDF-15）水平的影響。方法 選取2013年8月-2018年2月湖北省天門市第一人民醫(yī)院住院的120例帕金森病患者作為研究對象，按照隨機(jī)數(shù)字表將患者隨機(jī)分為對照組和觀察組，每組患者60例。對照組患者口服多巴絲肼片，根據(jù)患者的臨床癥狀及疾病嚴(yán)重程度，首次劑量為1/2片，3次/d，每周增加1/2片，根據(jù)患者的疾病嚴(yán)重程度，維持劑量為2~4片/d。觀察組患者在此基礎(chǔ)上聯(lián)合使用艾地苯醌片，30 mg/次，3次/d。兩組患者均治療3個月。觀察兩組患者的臨床療效，同時比較兩組治療前后的運(yùn)動功能和血清學(xué)指標(biāo)。結(jié)果 觀察組患者的治療有效率為75.00%，顯著高于對照組的55.00%，差異存在統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者的帕金森病統(tǒng)一評分量表第三部分（UPDRS Ⅲ）、帕金森病運(yùn)動功能評定量表（MDRSPD）顯著降低，左手計時運(yùn)動次數(shù)、右手計時運(yùn)動次數(shù)顯著升高（P<0.05），且觀察組患者的UPDRS Ⅲ、MDRSPD顯著低于對照組，左手計時運(yùn)動次數(shù)、右手計時運(yùn)動次數(shù)顯著高于對照組（P<0.05）。治療后，兩組患者的α-Syn、GDF-15水平均顯著降低（P<0.05），且觀察組患者的α-Syn、GDF-15水平顯著低于對照組（P<0.05）。結(jié)論 艾地苯醌聯(lián)合多巴絲肼治療帕金森患者效果顯著，可顯著降低α-Syn和GDF-15水平，建議臨床推廣。

Objective To investigate the clinical efficacy of idebenone combined levodopa and benserazide hydrochloride in treatment of Parkinson's disease, and its effect on α -Syn and GDF-15 levels. Methods A total of 120 patients with Parkinson's disease admitted to The First People's Hospital of Tianmen in Hubei Province from August 2013 to February 2018 were selected as the study subjects. According to the random number table, the patients were randomly divided into the control group and observation group, with 60 patients in each group. Patients in the control group were po administered with Levodopa and Benserazide Hydrochloride Tablets, the first dose was 1/2 tablet, 3 times daily, and 1/2 tablet was added weekly according to the clinical symptoms and disease severity of the patients. The maintenance dose was 2-4 tablets daily. Patients in the observation group were po administered with Idebenone Tablets on the basis of control group, 30 mg/time, and 3 times daily. Patients in both groups were treated for 3 months. The clinical efficacy of the two groups was observed, and the motor function and serological indexes were compared before and after treatment. Results The effective rate of patients in the observation group was 75.00%, which was significantly higher than 55.00% in the control group, with statistically significant difference (P<0.05). After treatment, UPDRS Ⅲ, MDRSPD scores in two groups were decreased significantly, and the left hand timing movement frequency, right timing movement times were significantly increased (P<0.05), and UPDRS Ⅲ and MDRSPD scores were significantly lower than those in the control group, the left hand timing movement number of times, right timing movement were significantly higher than those in the control group (P<0.05). After treatment, the levels of α-Syn and GDF-15 in two groups were significantly decreased (P<0.05), and the levels ofα-Syn and GDF-15 in the observation group were significantly lower than those in the control group (P<0.05). Conclusion The combination of idebenone combined levodopa and benserazide hydrochloride is effective in treatment of Parkinson's disease, which can significantly reduce the levels of α-Syn and GDF-15, suggesting clinical promotion.

R971